| Generation of human memory stem T cells after haploidentical T-replete hematopoietic stem cell transplantation N Cieri, G Oliveira, R Greco, M Forcato, C Taccioli, B Cianciotti, ... Blood, The Journal of the American Society of Hematology 125 (18), 2865-2874, 2015 | 171 | 2015 |
| TCR redirected T cells for cancer treatment: achievements, hurdles, and goals F Manfredi, BC Cianciotti, A Potenza, E Tassi, M Noviello, A Biondi, ... Frontiers in immunology 11, 1689, 2020 | 104 | 2020 |
| CD4+ memory stem T cells recognizing citrullinated epitopes are expanded in patients with rheumatoid arthritis and sensitive to tumor necrosis factor blockade BC Cianciotti, E Ruggiero, C Campochiaro, G Oliveira, ZI Magnani, ... Arthritis & rheumatology 72 (4), 565-575, 2020 | 49 | 2020 |
| Tailored chemokine receptor modification improves homing of adoptive therapy T cells in a spontaneous tumor model S Garetto, C Sardi, E Martini, G Roselli, D Morone, R Angioni, ... Oncotarget 7 (28), 43010, 2016 | 43 | 2016 |
| CRISPR-based gene disruption and integration of high-avidity, WT1-specific T cell receptors improve antitumor T cell function E Ruggiero, E Carnevale, A Prodeus, ZI Magnani, B Camisa, I Merelli, ... Science translational medicine 14 (631), eabg8027, 2022 | 33 | 2022 |
| Revealing and harnessing CD39 for the treatment of colorectal cancer and liver metastases by engineered T cells A Potenza, C Balestrieri, M Spiga, L Albarello, F Pedica, F Manfredi, ... Gut 72 (10), 1887-1903, 2023 | 15 | 2023 |
| Flow cytometry data mining by cytoChain identifies determinants of exhaustion and stemness in TCR‐engineered T cells F Manfredi, D Abbati, BC Cianciotti, L Stasi, A Potenza, E Ruggiero, ... European Journal of Immunology 51 (8), 1992-2005, 2021 | 13 | 2021 |
| TIM-3, LAG-3, or 2B4 gene disruptions increase the anti-tumor response of engineered T cells BC Cianciotti, ZI Magnani, A Ugolini, B Camisa, I Merelli, V Vavassori, ... Frontiers in Immunology 15, 1315283, 2024 | 3 | 2024 |
| T Cell Features in Glioblastoma May Guide Therapeutic Strategies to Overcome Microenvironment Immunosuppression A Losurdo, A Di Muzio, BC Cianciotti, A Dipasquale, P Persico, ... Cancers 16 (3), 603, 2024 | 3 | 2024 |
| Harnessing T cell exhaustion and trogocytosis to isolate patient-derived tumor-specific TCR F Manfredi, L Stasi, S Buonanno, F Marzuttini, M Noviello, S Mastaglio, ... Science Advances 9 (48), eadg8014, 2023 | 3 | 2023 |
| 780 Treatment of ovarian cancer cells with olaparib and trabectedin modulates the expression of immune-related molecules and the killing ability of TCR-edited T cells A Bergamini, E Tassi, F Trippitelli, MC Maffia, M Candiani, L Bocciolone, ... International Journal of Gynecologic Cancer 34 (Suppl 1), 2024 | | 2024 |
| Generating universal anti-CD19 CAR T cells with a defined memory phenotype by CRISPR/Cas9 editing and safety evaluation of the transcriptome BC Cianciotti, R Sugimura, K Benabdellah, K Pavlovic, ... | | 2024 |
| Harnessing CD39 for the treatment of colorectal cancer and liver metastases by engineered T cells A Potenza, C Balestrieri, L Albarello, F Pedica, M Spiga, F Manfredi, ... Cancer Research 83 (7_Supplement), 902-902, 2023 | | 2023 |
| CRISPR/Cas9-mediated CD39 disruption can be combined with TCR editing in T cells to improve the adoptive T cell therapy of colorectal cancer A Potenza, C Balestrieri, L Albarello, F Pedica, L Stasi, F Manfredi, ... Cancer Research 82 (12_Supplement), 567-567, 2022 | | 2022 |
| Multidirectional dysfunction of the immune response in patients with systemic lupus erythematosus GA Ramirez Università Vita-Salute San Raffaele, 2022 | | 2022 |
| CRISPR/Cas9-mediated CD39 disruption can be combined with TCR editing in T cells to improve the adoptive T cell therapy of colorectal cancer A Potenza, L Albarello, L Stasi, F Manfredi, M Spiga, E Tassi, ... HUMAN GENE THERAPY 32 (19-20), A33-A33, 2021 | | 2021 |
| Tim-3, LAG-3 and 2B4 disruptions differentially regulate anti-tumor response of TCR gene edited memory stem T cells BC Cianciotti, ZI Magnani, B Camisa, A Potenza, V Vavassori, L Naldini, ... HUMAN GENE THERAPY 32 (19-20), A7-A7, 2021 | | 2021 |
| Exploiting genome editing and WT1-specific T cell receptors to redirect T lymphocytes against acute myeloid leukemia E Ruggiero, E Carnevale, A Prodeus, A Potenza, Z Magnani, B Camisa, ... HUMAN GENE THERAPY 32 (19-20), A92-A92, 2021 | | 2021 |
| Crispr-Based Replacement of The Endogenous T-Cell Repertoire With Novel, High-Avidity, Natural T Cell Receptors To WT1 For The Treatment of Acute Myeloid Leukemia E Ruggiero, E Carnevale, A Prodeus, Z Magnani, B Camisa, C Politano, ... BONE MARROW TRANSPLANTATION 56 (SUPPL 1), 48-48, 2021 | | 2021 |
| LAG-3, Tim-3 or 2B4 Disruption Differentially Regulate the Anti-Tumor Response of TCR Gene-Edited Human Memory Stem T Cells BC Cianciotti, ZI Magnani, B Camisa, M Di Bono, A Potenza, V Vavassori, ... MOLECULAR THERAPY 29 (4), 301-301, 2021 | | 2021 |
